◆ mixed
Impact
PhaseFiled/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to marketIR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
deucrictibant Updated Jul 6
What to watch
Two binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.
Bull case
- RAPIDe-3 Phase 3 data was robust, met all primary and 11 secondary endpoints with high statistical significance (p<0.0001), including median symptom relief in 1.28 hours and complete resolution in 11.95 hours, positioning it as a potentially best-in-class oral option.
- If approved, deucrictibant would be the first oral bradykinin B2 receptor antagonist for HAE, a novel mechanism versus sebetralstat's kallikrein inhibition, potentially offering differentiation in efficacy or tolerability.
- The prophylactic XR formulation addresses a larger commercial market than on-demand treatment alone; Phase 2 CHAPTER-1 data showed 84.5% reduction in monthly attack rates, and the CHAPTER-3 readout (Q3 2026) could open that opportunity.
Bear case
- KalVista's sebetralstat (EKTERLY) was FDA-approved in July 2025 as the first oral on-demand HAE therapy, a full ~2 years ahead of deucrictibant's April 2027 PDUFA, giving it a massive head start in brand awareness, physician adoption, and formulary access.
- The FDA previously placed a clinical hold on deucrictibant in 2022 over preclinical safety concerns (since resolved), but the history introduces residual regulatory risk.
- CHAPTER-3 topline results (Q3 2026) are a binary binary event, if the XR formulation fails to meet endpoints, the prophylactic opportunity collapses and the stock would likely re-rate sharply lower.